E. I. B. M. Mahidin Et Al. , "Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women with Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer," Journal of Clinical Oncology , vol.42, no.23, pp.2812-2821, 2024
Mahidin, E. I. B. M. Et Al. 2024. Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women with Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Journal of Clinical Oncology , vol.42, no.23 , 2812-2821.
Mahidin, E. I. B. M., Im, S., Rihani, J., Chung, W., Babu, K. G., Bowles, J., ... Alfaro, T. D.(2024). Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women with Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Journal of Clinical Oncology , vol.42, no.23, 2812-2821.
Mahidin, Eznal Et Al. "Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women with Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer," Journal of Clinical Oncology , vol.42, no.23, 2812-2821, 2024
Mahidin, Eznal I. Et Al. "Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women with Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer." Journal of Clinical Oncology , vol.42, no.23, pp.2812-2821, 2024
Mahidin, E. I. B. M. Et Al. (2024) . "Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women with Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer." Journal of Clinical Oncology , vol.42, no.23, pp.2812-2821.
@article{article, author={Eznal Izwadi Bin Mohd Mahidin Et Al. }, title={Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women with Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer}, journal={Journal of Clinical Oncology}, year=2024, pages={2812-2821} }